|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM155298615 |
| 003 |
DE-627 |
| 005 |
20231223071830.0 |
| 007 |
tu |
| 008 |
231223s2005 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0518.xml
|
| 035 |
|
|
|a (DE-627)NLM155298615
|
| 035 |
|
|
|a (NLM)15885641
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Deng, Jing-Min
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Effects of allergen inhalation and oral glucocorticoid on concentrations of serum-soluble CD86 in allergic asthmatics
|
| 264 |
|
1 |
|c 2005
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 24.06.2005
|
| 500 |
|
|
|a Date Revised 16.11.2017
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a The aim of the present study was to investigate effects of allergen inhalation and oral glucocorticoid on concentration of serum soluble CD86 in patients with allergic asthma. Our results showed that the serum soluble CD86 concentrations in the dual responder group increased from 491.8 +/- 15.4 IU/ml before allergen inhalation to 603.8 +/- 19.3 IU/ml 24 h after allergen inhalation. In the isolated early responders, there was no significant increase in serum soluble CD86 concentrations after allergen inhalation compared with baseline levels. There was a significant decrease in serum soluble CD86 concentrations after 2 weeks of glucocorticoid therapy (448.3 +/- 15.1 IU/ml) compared with baseline values (532.7 +/- 12.3 IU/ml), whereas there was no significant difference in the placebo group. This study has demonstrated that serum soluble CD86 concentrations increased after allergen inhalation in sensitized asthmatic subjects, and that serum sCD86 concentrations were downregulated by prednisolone therapy
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Allergens
|2 NLM
|
| 650 |
|
7 |
|a Antigens, CD
|2 NLM
|
| 650 |
|
7 |
|a B7-2 Antigen
|2 NLM
|
| 650 |
|
7 |
|a CD86 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Glucocorticoids
|2 NLM
|
| 650 |
|
7 |
|a Membrane Glycoproteins
|2 NLM
|
| 650 |
|
7 |
|a Prednisolone
|2 NLM
|
| 650 |
|
7 |
|a 9PHQ9Y1OLM
|2 NLM
|
| 700 |
1 |
|
|a Shi, Huan-Zhong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Qin, Xue-Jun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xie, Zheng-Fu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Huang, Chun-Ping
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhong, Xiao-Ning
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 115(2005), 2 vom: 15. Mai, Seite 178-83
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:115
|g year:2005
|g number:2
|g day:15
|g month:05
|g pages:178-83
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 115
|j 2005
|e 2
|b 15
|c 05
|h 178-83
|